22.02.2013 - Molecular diagnostics and lab provider Qiagen is entering the highly competitive market of Next-Generation Sequencing (NGS) benchtop sequencers.
The company presented a sample-to-result Next-Generation Sequencing workflow designed for clinical research and diagnostics at the AGBT meeting in Florida. However, its sample preparation, newly introduced benchtop sequencer GeneReaderTM and bioinformatics solution is for research use only, as those are of its competitors Roche, Illumina and Life Technologies. However, the announcement suggested that the Dutch-German company’s NGS workflow is automated from primary sample to digital result.
"Next-generation sequencing is making a transformational impact on life science, but challenges are limiting more widespread adoption for clinical purposes," said Peer M. Schatz, CEO of QIAGEN. "The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content and services."
No sequencing firm currently has a NGS workflow that is simple and reliable enough for diagnostic purposes. However, all of them aim at establishing highly automated and inter-laboratory reproducible NGS procedures that can be used by non-specialists. The adoption of NGS in fields such as clinical research and diagnostics is still hampered by workflow challenges, manual sample preparation processes, the speed, comparability and quality of data analysis.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.
04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.